Why the study?
The role of body composition parameters in patients with MASLD regarding the presence and severity of CAC was not fully elucidated.
Is visceral obesity associated with the presence and severity of coronary artery calcification in patients with metabolic dysfunction-associated steatotic liver disease?
Is visceral obesity associated with the presence and severity of coronary artery calcification in patients with metabolic dysfunction-associated steatotic liver disease?
In patients with metabolic dysfunction-associated steatotic liver disease, CT-derived visceral obesity is independently associated with severe coronary artery calcification, highlighting its potential as a prognostic radiological biomarker.
Visceral obesity may flag higher severe CAC risk in MASLD; hypothesis-generating and requires prospective validation before clinical use.
Background/Objectives: The role of body composition parameters in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with presence and severity of coronary artery calcification (CAC) is still not fully elucidated. We aimed to evaluate the impact of computed tomography (CT)-based body composition parameters in patients with MASLD with CAC severity. Methods: In this multicenter study, 1870 individuals underwent cardiac CT for the detection of CAC as well as ultrasonography for the diagnosis of hepatic steatosis. The presence of CAC was defined by a CAC score threshold of >0, while severe CAC was defined by a threshold of >300. Using the abdominal cross-sectional CT images at the L3 vertebra level, we analyzed the skeletal muscle index, visceral to subcutaneous adipose tissue ratio, and muscle density using the Hounsfield unit. Results: Of 648 patients with MASLD, the proportions of presence of CAC and severe CAC were 45.2% and 9.9%, respectively. Visceral obesity was not associated with the presence of CAC after adjustment for age, sex, smoking, statin therapy, type 2 diabetes, and advanced fibrosis (adjusted odds ratio (aOR), 1.38; 95% confidence interval (CI), 0.86–2.23; p = 0.180). However, visceral obesity was independently associated with severe CAC after adjustment for several metabolic risk factors (aOR, 3.54; 95% CI, 1.25–14.90; p = 0.039), and adjustment for atherosclerotic cardiovascular disease risk scores (aOR, 3.74; 95% CI, 1.31–15.79; p = 0.032). Conclusions: Visceral obesity may serve as a novel prognostic CT-based radiological biomarker for patients with MASLD with severe CAC.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: